As of 2025-09-18, the EV/EBITDA ratio of Vanda Pharmaceuticals Inc (VNDA) is -2.62. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. VNDA's latest enterprise value is 183.74 mil USD. VNDA's TTM EBITDA according to its financial statements is -70.05 mil USD. Dividing these 2 quantities gives us the above VNDA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.9x - 14.1x | 11.0x |
| Forward P/E multiples | 16.4x - 26.6x | 18.3x |
| Fair Price | (18.14) - (15.39) | (16.09) |
| Upside | -513.2% - -450.5% | -466.4% |
| Date | EV/EBITDA |
| 2025-09-17 | -2.62 |
| 2025-09-16 | -2.68 |
| 2025-09-15 | -2.61 |
| 2025-09-12 | -2.72 |
| 2025-09-11 | -2.80 |
| 2025-09-10 | -2.70 |
| 2025-09-09 | -2.72 |
| 2025-09-08 | -2.76 |
| 2025-09-05 | -2.81 |
| 2025-09-04 | -2.83 |
| 2025-09-03 | -2.90 |
| 2025-09-02 | -2.89 |
| 2025-08-29 | -2.91 |
| 2025-08-28 | -2.88 |
| 2025-08-27 | -2.82 |
| 2025-08-26 | -2.86 |
| 2025-08-25 | -2.81 |
| 2025-08-22 | -2.93 |
| 2025-08-21 | -2.72 |
| 2025-08-20 | -2.80 |
| 2025-08-19 | -2.74 |
| 2025-08-18 | -2.77 |
| 2025-08-15 | -2.60 |
| 2025-08-14 | -2.66 |
| 2025-08-13 | -2.60 |
| 2025-08-12 | -2.56 |
| 2025-08-11 | -2.45 |
| 2025-08-08 | -2.46 |
| 2025-08-07 | -2.46 |
| 2025-08-06 | -2.48 |
| 2025-08-05 | -2.47 |
| 2025-08-04 | -2.51 |
| 2025-08-01 | -2.45 |
| 2025-07-31 | -2.51 |
| 2025-07-30 | -2.86 |
| 2025-07-29 | -2.87 |
| 2025-07-28 | -2.88 |
| 2025-07-25 | -2.92 |
| 2025-07-24 | -2.96 |
| 2025-07-23 | -3.00 |
| 2025-07-22 | -2.89 |
| 2025-07-21 | -2.85 |
| 2025-07-18 | -2.95 |
| 2025-07-17 | -3.02 |
| 2025-07-16 | -2.98 |
| 2025-07-15 | -2.94 |
| 2025-07-14 | -3.11 |
| 2025-07-11 | -2.92 |
| 2025-07-10 | -3.13 |
| 2025-07-09 | -3.15 |